[Requirement for blood in hemodialyzed patients with chronic renal failure in the period before and after introduction to erythropoietin (r-HuEPO) treatment].
The present paper aimed to assess the influence of EPO-therapy on the requirement of blood transfusion in haemodialysed patients with end-stage renal failure. As shown in this paper, introduction of r-HuEPO into the therapy of uraemic anaemia almost completely eliminated the request for blood transfusion in these patients. EPO therapy did not influence significantly to the serum creatinine concentration and mean arterial blood pressure in these patients.
Wiecek
A
A
Katedry i Kliniki Nefrologii Slaskiej Akademii Medycznej w Katowicach.
Kokot
F
F
Spiechowicz
U
U
Cieplok
J
J
Czerwieńska
B
B
Strzelczyk
P
P
Dyjas
R
R
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D001803:Blood Transfusion; D003404:Creatinine / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012189:Retrospective Studies
D011994:Recombinant Proteins; D004921:Erythropoietin; D003404:Creatinine
Zapotrzebowanie na krew u hemodializowanych chorych na przewlekła niewydolność nerek w okresie przed po wprowadzeniu do leczenia erytropoetyny (r-HuEPO).